Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 7 | 2021 | 13 | 1.840 |
Why?
|
| Lung Injury | 3 | 2020 | 10 | 1.370 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2020 | 36 | 1.150 |
Why?
|
| Lung | 2 | 2019 | 169 | 1.070 |
Why?
|
| Reperfusion Injury | 3 | 2021 | 6 | 1.010 |
Why?
|
| Primary Graft Dysfunction | 3 | 2021 | 5 | 0.870 |
Why?
|
| Macrophages, Alveolar | 2 | 2021 | 5 | 0.860 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2019 | 4 | 0.780 |
Why?
|
| Epidemics | 1 | 2021 | 2 | 0.710 |
Why?
|
| Autoimmunity | 2 | 2019 | 14 | 0.690 |
Why?
|
| Endotoxins | 1 | 2020 | 14 | 0.680 |
Why?
|
| Monocytes | 4 | 2023 | 61 | 0.650 |
Why?
|
| Graft Rejection | 2 | 2019 | 69 | 0.650 |
Why?
|
| Forkhead Transcription Factors | 2 | 2020 | 24 | 0.650 |
Why?
|
| Autoantibodies | 1 | 2019 | 82 | 0.590 |
Why?
|
| Animals | 14 | 2021 | 3681 | 0.530 |
Why?
|
| Antigens | 1 | 2015 | 12 | 0.480 |
Why?
|
| Gene Transfer Techniques | 1 | 2015 | 30 | 0.480 |
Why?
|
| Hepatocytes | 1 | 2015 | 12 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 22 | 0.470 |
Why?
|
| Peptide Fragments | 1 | 2015 | 76 | 0.460 |
Why?
|
| Insulin | 1 | 2015 | 91 | 0.450 |
Why?
|
| Mice | 9 | 2021 | 1449 | 0.390 |
Why?
|
| Neoplasms | 2 | 2023 | 242 | 0.330 |
Why?
|
| Lentivirus | 3 | 2015 | 11 | 0.330 |
Why?
|
| Neutrophils | 3 | 2020 | 101 | 0.330 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 43 | 0.310 |
Why?
|
| Liver | 3 | 2015 | 151 | 0.300 |
Why?
|
| Immune Tolerance | 3 | 2017 | 16 | 0.280 |
Why?
|
| Humans | 17 | 2023 | 27307 | 0.260 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 225 | 0.240 |
Why?
|
| Transcriptome | 3 | 2019 | 91 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 1 | 0.210 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2020 | 23 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 19 | 0.210 |
Why?
|
| Antigens, CD | 1 | 2023 | 53 | 0.200 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 9 | 0.200 |
Why?
|
| Genetic Therapy | 2 | 2013 | 86 | 0.200 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 1 | 0.180 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2020 | 1 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 28 | 0.170 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 143 | 0.170 |
Why?
|
| Neutrophil Infiltration | 1 | 2020 | 9 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2021 | 71 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2021 | 71 | 0.170 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 37 | 0.170 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2023 | 258 | 0.170 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Collagen Type V | 1 | 2019 | 5 | 0.160 |
Why?
|
| Tubulin | 1 | 2019 | 16 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2019 | 43 | 0.160 |
Why?
|
| Autoantigens | 1 | 2019 | 26 | 0.160 |
Why?
|
| Collagen Type I | 1 | 2019 | 20 | 0.160 |
Why?
|
| Stem Cells | 1 | 2019 | 39 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2020 | 165 | 0.150 |
Why?
|
| Immunotherapy | 3 | 2023 | 59 | 0.150 |
Why?
|
| Epithelial Cells | 1 | 2019 | 104 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 43 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 35 | 0.150 |
Why?
|
| Transgenes | 2 | 2015 | 12 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 53 | 0.150 |
Why?
|
| Genetic Vectors | 2 | 2015 | 59 | 0.140 |
Why?
|
| Cells, Cultured | 1 | 2019 | 527 | 0.140 |
Why?
|
| Registries | 1 | 2018 | 201 | 0.140 |
Why?
|
| CD36 Antigens | 1 | 2017 | 1 | 0.140 |
Why?
|
| Aorta | 1 | 2017 | 17 | 0.130 |
Why?
|
| Exosomes | 1 | 2016 | 7 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 86 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2016 | 14 | 0.130 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 63 | 0.130 |
Why?
|
| Macrophages | 1 | 2017 | 116 | 0.130 |
Why?
|
| Allografts | 1 | 2017 | 216 | 0.120 |
Why?
|
| Integrases | 1 | 2015 | 4 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 23 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2016 | 77 | 0.120 |
Why?
|
| Factor IX | 1 | 2013 | 7 | 0.110 |
Why?
|
| Hemophilia B | 1 | 2013 | 11 | 0.110 |
Why?
|
| Immunity | 1 | 2013 | 16 | 0.100 |
Why?
|
| Disease Progression | 1 | 2015 | 672 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 454 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 178 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2018 | 311 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 103 | 0.080 |
Why?
|
| Male | 6 | 2021 | 14887 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 313 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 606 | 0.060 |
Why?
|
| Cell Line | 2 | 2016 | 292 | 0.060 |
Why?
|
| Ipilimumab | 1 | 2023 | 4 | 0.050 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2023 | 3 | 0.050 |
Why?
|
| Synovial Membrane | 1 | 2023 | 56 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 102 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2022 | 28 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 11 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 287 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 243 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2018 | 9 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2018 | 22 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 35 | 0.040 |
Why?
|
| Quality Control | 1 | 2018 | 27 | 0.040 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2018 | 1 | 0.040 |
Why?
|
| Graft Survival | 1 | 2018 | 97 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2018 | 7 | 0.040 |
Why?
|
| Software | 1 | 2018 | 61 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 261 | 0.040 |
Why?
|
| Spleen | 1 | 2018 | 33 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2018 | 79 | 0.040 |
Why?
|
| Illinois | 1 | 2018 | 250 | 0.040 |
Why?
|
| Cell Movement | 1 | 2018 | 82 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 350 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 79 | 0.030 |
Why?
|
| Aortitis | 1 | 2017 | 2 | 0.030 |
Why?
|
| Female | 3 | 2019 | 15334 | 0.030 |
Why?
|
| Endothelium | 1 | 2017 | 14 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 112 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 31 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 488 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 28 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2016 | 11 | 0.030 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 184 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 60 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 631 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 290 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 1444 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 624 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 561 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1807 | 0.030 |
Why?
|
| Antibodies | 1 | 2013 | 46 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 808 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 56 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1903 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 893 | 0.020 |
Why?
|
| Child | 1 | 2016 | 1269 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 2185 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 3551 | 0.020 |
Why?
|
| Adult | 1 | 2018 | 7945 | 0.020 |
Why?
|
| Middle Aged | 1 | 2018 | 9068 | 0.020 |
Why?
|